Nalaganje...
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis
The use of rituximab (RTX), an anti-CD20 monoclonal antibody (Ab), in refractory myasthenia gravis (MG) is associated with a better response in patients with Abs to the muscle-specific tyrosine kinase (MuSK) than in other MG subgroups. Anti-MuSK Abs are mostly IgG4 with proven pathogenicity and posi...
Shranjeno v:
| izdano v: | Front Immunol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7214629/ https://ncbi.nlm.nih.gov/pubmed/32431692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00613 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|